Benzyl N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valinate

Catalog No. :
ACWFHU142
CAS No. :
1894176-44-3
Molecular Formula :
C31H35N5O3
Molecular Weight :
525.65

IUPAC Name:(S)-Benzyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate

Benzyl N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valinate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameBenzyl N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valinate
IUPAC Name(S)-Benzyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate
Molecular FormulaC31H35N5O3
Molecular Weight525.65
SMILESCC(C)[C@@H](C(OCC1=CC=CC=C1)=O)N(CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)C(CCCC)=O
InChI KeyVXKKFWDUSKMRNO-LJAQVGFWSA-N
Synonymrac-Valsartan EP Impurity B;Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, phenylmethyl ester;rac-Valsartan EP Impurity B (rac-Valsartan USP Related Compound C);Benzyl 2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoate (rac-Valsartan Impurity)
CAS No.1894176-44-3

Synthetic Route by SureRoute

1. ACWFHU142 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHHQF788 route compound structure diagram
    ACHHQF788137864-22-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWFHU142 route product structure diagram
    ACWFHU1421894176-44-3
Inquiry

2. ACWFHU142 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWFHU142 route product structure diagram
    ACWFHU1421894176-44-3
Inquiry

Comments (0)